Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Everyone has probably dealt with at least a little physical pain in their life.But fortunately, the number of peop ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Patients can now receive interventional techniques that are no longer palliative in nature,” stated Samir Khan, DO, provider ...

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

A study on older adults in long-term care communities who experience pain found that it is linked to sleep quality and care dependency. That is, more severe pain is associated with poorer sleep ...

Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% ...

Neuronoff Inc., a Cleveland startup developing minimally invasive neuromodulation systems, has been awarded or recommended ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Adolore BioTherapeutics (”Adolore” or the “Company”), is developing intracellularly-delivered neuromodulators that naturally reduce neuronal excitability to restore balance to the PNS/CNS to treat the ...